Tech Company Financing Transactions
SpyGlass Pharma Funding Round
Sands Capital Management, Gilde Healthcare Partners and New Enterprise Associates joined a $75 million Series D funding round for SpyGlass Pharma. The financing closed on 6/2/2025.
Transaction Overview
Company Name
Announced On
6/2/2025
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series D
Investors
Proceeds Purpose
The funding will support the advancement of SpyGlass Pharma's cutting-edge Drug Delivery Platform through the readout of two registrational Phase III trials, set to begin later this year.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
27081 Aliso Creek Rd 125
Aliso Viejo, CA 92656
USA
Aliso Viejo, CA 92656
USA
Phone
Website
Email Address
Overview
SpyGlass Pharma brings together our industry's brightest engineers, scientists and clinicians to develop life-changing treatment options for patients suffering from ophthalmic diseases. Together we work toward our singular focus: Long-term drug delivery--that lasts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Mooney
Chief Operating Officer
James Dennewill
Chief Technical Officer
Glenn Sussman
President
Malik Kahook
Browse more venture capital transactions:
Prev: 6/2/2025: cove venture capital transaction
Next: 6/2/2025: GC AI venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs